- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06098651
En studie av DCR-STAT3 hos voksne med solide svulster
En åpen, fase 1-studie for å evaluere sikkerheten, tolerabiliteten og farmakokinetikken til intravenøs DCR-STAT3 hos voksne med refraktære solide svulster
This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The primary goal of this first-in-human study is to assess the safety and tolerability of DCR-STAT3 in adults with refractory solid tumors. Secondary study goals are to evaluate potential antitumor effects of STAT3 knockdown, as assessed by circulating blood biomarkers indicative of immune activation, as well as any direct impact on tumor size by appropriate imaging and RECIST 1.1 criteria. Antitumor effects will be evaluated for DCR-STAT3 as a monotherapy.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Texas
-
Dallas, Texas, Forente stater, 75039
- Next Oncology
-
San Antonio, Texas, Forente stater, 78229
- Next Oncology
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age
- ≥ 18 years of age inclusive, at the time of signing the informed consent.
Type of Participant and Disease Characteristics
- Documented locally advanced or metastatic solid tumor malignancy or non-Hodgkin's lymphoma that is refractory to standard therapy known to provide clinical benefit for their condition or for which no standard therapy is available
- Demonstrated evidence of disease progression, via imaging, during or following standard therapy known to provide clinical benefit for their condition
- Demonstrated intolerance to standard therapy known to provide clinical benefit for their condition
- Measurable disease according to RECIST version 1.1 (as determined by CT or MRI)
- Malignancy not currently amenable to surgical intervention due to medical contraindication or non-resectability of the tumor
- ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months
Weight
- BMI ≥ 18 kg/m2
Sex
Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 24 weeks after the last dose of study intervention:
-
Refrain from donating sperm
AND, either:
-
Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
-
Must agree to use a male condom when having sexual intercourse with a WOCBP who is not currently pregnant
Female participants are eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:
-
Is not a WOCBP OR
-
Is a WOCBP and:
is using a contraceptive method that is highly effective, with a failure rate of < 1%, as described in Section 10.4 during the study intervention period and for at least 24 weeks after the last dose of study intervention. The Investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.
must have a negative highly sensitive pregnancy test (serum as required by local regulations) on Day 1 of each cycle before the first dose of study intervention
Exclusion Criteria:
Prior/Concomitant Therapy
- Other concurrent (within 28 days of Day 1, Cycle 1) chemotherapy, immunotherapy, or radiotherapy. Note that hormonal therapy (e.g., tamoxifen, LHRH agonists) is allowed.
- Requirement for palliative radiotherapy to lesions that are defined as target lesions by RECIST version 1.1 criteria at the time of study entry
- Continued compromise or inadequate recovery from a prior anti-neoplastic therapy
- Known hypersensitivity to any of the components of DCR-STAT3
- Long-term immunosuppressive therapy
Prior/Concurrent Clinical Study Experience
- Treatment with investigational therapy(ies) within 5 half-lives of the investigational therapy prior to the first scheduled day of dosing with DCR-STAT3, or 4 weeks if the half-life of the investigational agent is not known
Diagnostic assessments - Seropositive for antibodies to HIV, HBV, or HCV at Screening (historical testing may be used if performed within the 3 months prior to screening). NOTE: In participants with previous treatment for hepatitis C with direct-acting HCV medication and seropositivity for HCV, or in participants with prior infection and spontaneous resolution, HCV RNA must be undetectable (at least 2 negative HCV RNA tests at least 12 weeks apart), and the HCV infection must have been resolved or cured > 3 years prior to initial dosing with the investigational medication.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: DCR-STAT3
DCR-STAT3 |
DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events and dose limiting toxicities
Tidsramme: Cycle 1 (8 weeks)
|
safety and tolerability |
Cycle 1 (8 weeks)
|
|
Severity of adverse events
Tidsramme: Cycle 1 (8 weeks)
|
measured according to CTCAE 5.0 criteria |
Cycle 1 (8 weeks)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetic (AUC)
Tidsramme: Day 1 and Day 29 of Cycle 1 (each cycle is 8 weeks)
|
Area under the plasma concentration versus time curve |
Day 1 and Day 29 of Cycle 1 (each cycle is 8 weeks)
|
|
Pharmacokinetic (Urine)
Tidsramme: Day 1 and Day 29 of Cycle 1 (each cycle is 8 weeks)
|
Urinary excretion |
Day 1 and Day 29 of Cycle 1 (each cycle is 8 weeks)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: John Hanrahan, MD MPH, Dicerna Phamaceuticals, a Novo Nordisk Company
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- DCR-STAT3-101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .